LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Suchergebnis

Treffer 1 - 3 von insgesamt 3

Suchoptionen

  1. Artikel ; Online: Global research trends and hotspots of Helicobacter pylori eradication based on clinical trial registration platforms: A cross-sectional analysis.

    Guan, Jia-Lun / Feng, Li-Na / Han, Ying-Ying / Xia, Su-Hong / Zhao, Kai / Zhang, Ming-Yu / Zhang, Yu / Dong, Ruo-Nan / Huang, Yu-Jie / Li, Ji-Yan / Liao, Jia-Zhi / Li, Pei-Yuan

    Clinics and research in hepatology and gastroenterology

    2023  Band 47, Heft 10, Seite(n) 102233

    Abstract: Background: This study aimed to obtain an overview of clinical trials on Helicobacter pylori (H. pylori) eradication and analyze the global trends and hotspots in this field.: Methods: We collected the data from clinical trials focused on H. pylori ... ...

    Abstract Background: This study aimed to obtain an overview of clinical trials on Helicobacter pylori (H. pylori) eradication and analyze the global trends and hotspots in this field.
    Methods: We collected the data from clinical trials focused on H. pylori eradication in the primary clinical trial registries from 2000 to 2022 in the world. Then we analyzed the research trends and hotspots in H. pylori eradication regimens in different regions at different periods.
    Results: A total of 780 clinical trials were included, which were mainly conducted in Asia (682), followed by Europe (59), Africa (20), North America (16), South America (7), Oceania (2). The most active countries were China (343), Iran (140), South Korea (63), and Japan (73). "Bismuth-containing quadruple therapy (BQT)" was the most studied regimen (159, 20.38 %). Additionally, clinical trials focused on potassium-competitive acid blockers (P-CABs)-based therapy, probiotics, and high-dose dual therapy (HDDT) were constantly increasing. BQT received the most attention in China (26.53 %) and Iran (22.14 %), while it was tailored therapy in South Korea (23.29 %). P-CABs-based therapy was the main reseach hotspot in Japan (61.90 %).
    Conclusion: How to eradicate H. pylori infection has been a heated research topic. BQT, P-CABs-based therapy, probiotics, and HDDT attracted the most attention in recent years.
    Mesh-Begriff(e) Humans ; Anti-Bacterial Agents/therapeutic use ; Helicobacter pylori ; Cross-Sectional Studies ; Proton Pump Inhibitors/therapeutic use ; Drug Therapy, Combination ; Helicobacter Infections/drug therapy ; Bismuth/therapeutic use ; Amoxicillin/therapeutic use ; Treatment Outcome
    Chemische Substanzen Anti-Bacterial Agents ; Proton Pump Inhibitors ; Bismuth (U015TT5I8H) ; Amoxicillin (804826J2HU)
    Sprache Englisch
    Erscheinungsdatum 2023-10-24
    Erscheinungsland France
    Dokumenttyp Journal Article
    ZDB-ID 2594333-9
    ISSN 2210-741X ; 2210-7401
    ISSN (online) 2210-741X
    ISSN 2210-7401
    DOI 10.1016/j.clinre.2023.102233
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  2. Artikel ; Online: Determination of an Appropriate Endoscopic Monitoring Interval for Patients with Gastric Precancerous Conditions in China.

    Zhao, Kai / Feng, Li-Na / Xia, Su-Hong / Zhou, Wang-Dong / Zhang, Ming-Yu / Zhang, Yu / Dong, Ruo-Nan / Tian, De-An / Liu, Mei / Liao, Jia-Zhi

    Current medical science

    2023  Band 43, Heft 2, Seite(n) 268–273

    Abstract: Objective: Gastric precancerous conditions such as atrophic gastritis (AG) and intestinal metaplasia (IM) are considered independent risk factors for gastric cancer (GC). The suitable endoscopic monitoring interval is unclear when we attempt to prevent ... ...

    Abstract Objective: Gastric precancerous conditions such as atrophic gastritis (AG) and intestinal metaplasia (IM) are considered independent risk factors for gastric cancer (GC). The suitable endoscopic monitoring interval is unclear when we attempt to prevent GC development. This study investigated the appropriate monitoring interval for AG/IM patients.
    Methods: Totally, 957 AG/IM patients who satisfied the criteria for evaluation between 2010 and 2020 were included in the study. Univariate and multivariate analyses were used to determine the risk factors for progression to high-grade intraepithelial neoplasia (HGIN)/GC in AG/IM patients, and to determine an appropriate endoscopic monitoring scheme.
    Results: During follow-up, 28 AG/IM patients developed gastric neoplasia lesions including gastric low-grade intraepithelial neoplasia (LGIN) (0.7%), HGIN (0.9%), and GC (1.3%). Multivariate analysis identified H. pylori infection (P=0.022) and extensive AG/IM lesions (P=0.002) as risk factors for HGIN/GC progression (P=0.025).
    Conclusion: In our study, HGIN/GC was present in 2.2% of AG/IM patients. In AG/IM patients with extensive lesions, a 1-2-year surveillance interval is recommended for early detection of HIGN/GC in AG/IM patients with extensive lesions.
    Mesh-Begriff(e) Humans ; Gastritis, Atrophic/diagnosis ; Gastritis, Atrophic/epidemiology ; Gastritis, Atrophic/etiology ; Precancerous Conditions/diagnosis ; Precancerous Conditions/complications ; Precancerous Conditions/epidemiology ; Stomach Neoplasms/diagnosis ; Stomach Neoplasms/epidemiology ; Risk Factors ; Endoscopy/adverse effects
    Sprache Englisch
    Erscheinungsdatum 2023-03-02
    Erscheinungsland China
    Dokumenttyp Journal Article
    ZDB-ID 2931065-9
    ISSN 2523-899X ; 2096-5230
    ISSN (online) 2523-899X
    ISSN 2096-5230
    DOI 10.1007/s11596-023-2705-x
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

  3. Artikel ; Online: Impact of body size on efficacy of high-dose dual therapy for Helicobacter pylori eradication.

    Guan, Jia-Lun / Han, Ying-Ying / Wang, Mu-Ru / Xia, Su-Hong / Li, Ji-Yan / Zhang, Ming-Yu / Zhao, Kai / Feng, Li-Na / Zhang, Yu / Dong, Ruo-Nan / Liao, Jia-Zhi / Li, Pei-Yuan

    Helicobacter

    2023  Band 28, Heft 2, Seite(n) e12953

    Abstract: Background: High-dose dual therapy (HDDT) is an emerging and promising therapeutic regime for Helicobacter pylori (H. pylori) eradication. However, the pharmacokinetics of the components of HDDT, amoxicillin and proton pump inhibitor, are likely to be ... ...

    Abstract Background: High-dose dual therapy (HDDT) is an emerging and promising therapeutic regime for Helicobacter pylori (H. pylori) eradication. However, the pharmacokinetics of the components of HDDT, amoxicillin and proton pump inhibitor, are likely to be affected by body size. In this study, we aimed to find out the impact of body size on the efficacy of HDDT.
    Methods: We collected the medical data of 385 treatment-naive patients infected with H. pylori who received HDDT (esomeprazole 20 mg and amoxicillin 750 mg four times daily) for 14 days from July 2020 to December 2021. The associations among the eradication efficacy, adverse events, and variables (sex, age, height, body weight, body mass index (BMI), body surface area (BSA), smoking, drinking, etc.) were analyzed respectively in our study. Among these factors, continuous variables were classified into categorical variables using the cut-off values which were calculated by receiver operating characteristic analysis.
    Results: The eradication rate of HDDT was 89.9%. There were 55 (14.3%) patients who occurred adverse events during the treatment. Patients with height <170.5 cm, body weight <60.5 kg, BMI <20.55 kg/m
    Conclusion: HDDT could achieve better eradication efficacy in patients with small BSA. Clinicians should be aware of the impact of BSA on the H. pylori eradication rate and pay more attention to patients with large BSA.
    Mesh-Begriff(e) Humans ; Anti-Bacterial Agents/therapeutic use ; Helicobacter pylori ; Helicobacter Infections/drug therapy ; Drug Therapy, Combination ; Amoxicillin/therapeutic use ; Proton Pump Inhibitors/therapeutic use ; Body Size ; Body Weight ; Treatment Outcome ; Clarithromycin/therapeutic use
    Chemische Substanzen Anti-Bacterial Agents ; Amoxicillin (804826J2HU) ; Proton Pump Inhibitors ; Clarithromycin (H1250JIK0A)
    Sprache Englisch
    Erscheinungsdatum 2023-02-03
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 1330665-0
    ISSN 1523-5378 ; 1083-4389
    ISSN (online) 1523-5378
    ISSN 1083-4389
    DOI 10.1111/hel.12953
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Volltext online

    Zusatzmaterialien

    Kategorien

    Verfügbar in ZB MED Köln/Königswinter

    Zs.A 4801: Hefte anzeigen Standort:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Über subito bestellen

    Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.

Zum Seitenanfang